Knight CNS

active

IFC is considering providing an up to US$40 million loan to Knight Therapeutics Inc. (“Knight” or the “Company”), a pan-American (ex-USA) specialty pharmaceutical company headquartered in Canada with significant operations in Latin America, to partially finance the acquisition of the rights to manufacture, market and sell Exelon® (rivastigmine) in Canada and Latin America (the “Territory”), as well as an exclusive license to use the intellectual property and the Exelon® trademark, from Novartis within the Territory (the “Exelon Acquisition”). Exelon® is indicated for the symptomatic treatment of mild to moderately severe dementia in people with Alzheimer’s disease and Parkinson’s disease.Founded in 2014 in Montreal, Canada, Knight is pan-American (ex-USA) specialty pharmaceutical company that focused on acquiring or in-licensing and commercializing pharmaceutical products in Canada and Latin America.In 2019, Knight acquired a controlling stake in Grupo Biotoscana (“GBT”), a specialty pharmaceutical company with a presence across Latin America. In August 2020, Knight completed the 100% acquisition of GBT. With the GBT acquisition, Knight has expanded its operations in Latin America through a direct presence in 10 countries.